Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.39 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.39 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.39 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.36 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.36 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.36 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.36 |
| ▸ | GAPDH | P04406 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41364 | 0.90 | PI4KA (0.43) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| Nitrobenzene SCHEMBL28322736 | 0.88 | SLC29A1 (0.41) | SLC29A1SLC28A3 | |
| SCHEMBL160359 | 0.88 | EGFR (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL30515021 | 0.88 | EGFR (0.53) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| Phosphoric Acid SCHEMBL635802 | 0.84 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| Phosphoric Acid SCHEMBL28300969 | 0.83 | EGFR (0.48) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL27541459 | 0.79 | PI4KA (0.39) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL29974446 | 0.78 | PI4KA (0.40) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL14586077 | 0.78 | PI4KA (0.41) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL10365538 | 0.78 | SLC29A1 (0.39) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | claimed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | claimed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4045504-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | Ai-biopharma (FR) | 2022-08-24 | — | — | EP | claimed |
| WO-2022169634-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-08-11 | — | — | WO | claimed |
| WO-2021074443-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2021-04-22 | — | — | WO | claimed |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | disclosed |
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | A-BIOPHARMA (FR) | 2026-02-03 | — | — | US | disclosed |
| US-20250275946-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2025-09-04 | — | — | US | disclosed |
| WO-2024189607-A1 | METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR DISEASES TREATMENT | DIDENKO KIRILL (MX) | 2024-09-19 | — | — | WO | disclosed |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2024-05-02 | — | — | US | disclosed |
| WO-2022169634-A9 | COMBINATION THERAPY FOR THE TREATMENT OF CANCER | UNM RAINFOREST INNOVATIONS (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2006135602-A2 | HERPES VIRUS-BASED COMPOSITIONS AND METHODS OF USE IN THE PRENATAL AND PERINATAL PERIODS | UNIVERSITY OF ROCHESTER (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20050119284-A1 | ANTIVIRAL AGENTS AND METHODS OF USE | -, Wisconsin Alumni Research Foundation (US) | 2005-06-02 | — | — | US | disclosed |
| EP-1349555-A1 | TREATMENT OF CANCER BY REDUCTION OF INTRACELLULAR ENERGY AND PYRIMIDINES | Sloan-Kettering Institute For Cancer Research (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030139331-A1 | Treatment of cancer by reduction of intracellular energy and pyrimidines | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-07-24 | — | — | US | disclosed |
| EP-1239280-A2 | ElogDoct:A tool for lipophilicity determination in drug discovery basic and neutral compounds | Pfizer Products Inc. (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002045720-A1 | TREATMENT OF CANCER BY REDUCTION OF INTRACELLULAR ENERGY AND PYRIMIDINES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2002-06-13 | — | — | WO | disclosed |
| EP-1126277-A2 | Determination of log P coefficients via A RP-HPLC column | Pfizer Products Inc. (US) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12539332-B2 | Anti-viral and hepatic-targeted drugs | HAVCR2, NR1H4, NR1H3 | PI4KA 3407/4885PI4K2B 3778/4885PI4K2A 4002/4885 |
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | HAVCR2, NR1H4, NR1H3 | PI4KA 3176/4885PI4K2B 3413/4885PI4K2A 3685/4885 |
| US-20050119284-A1 | ANTIVIRAL AGENTS AND METHODS OF USE | APRT, SAMHD1, GART | PI4KA 2425/4885PI4K2B 2853/4885PI4K2A 3089/4885 |
| US-20240139325-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | SLC10A1, HAVCR2, HDGF | PI4KA 1840/4885PI4K2B 2425/4885PI4K2A 3004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.